Article Type
Changed
Fri, 02/01/2019 - 09:09
Display Headline
COX-2 inhibitors and cardiovascular risk: The data are inconclusive, and these drugs are needed
Article PDF
Author and Disclosure Information

John Lipani, MD
Clinical rheumatologist and researcher; president, Histatek Inc., Fountain Hills, AZ

Address: John Lipani, MD, 16107 East Emerald Drive, #102, Fountain Hills, AZ 85268

Issue
Cleveland Clinic Journal of Medicine - 68(11)
Publications
Topics
Page Number
961-962
Sections
Author and Disclosure Information

John Lipani, MD
Clinical rheumatologist and researcher; president, Histatek Inc., Fountain Hills, AZ

Address: John Lipani, MD, 16107 East Emerald Drive, #102, Fountain Hills, AZ 85268

Author and Disclosure Information

John Lipani, MD
Clinical rheumatologist and researcher; president, Histatek Inc., Fountain Hills, AZ

Address: John Lipani, MD, 16107 East Emerald Drive, #102, Fountain Hills, AZ 85268

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 68(11)
Issue
Cleveland Clinic Journal of Medicine - 68(11)
Page Number
961-962
Page Number
961-962
Publications
Publications
Topics
Article Type
Display Headline
COX-2 inhibitors and cardiovascular risk: The data are inconclusive, and these drugs are needed
Display Headline
COX-2 inhibitors and cardiovascular risk: The data are inconclusive, and these drugs are needed
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media